Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Oncology · Medullary Thyroid Carcinoma

Medullary Thyroid Carcinoma (MTC) Treatment and Management

At a Glance

Medullary Thyroid Carcinoma (MTC) is a rare thyroid cancer treated primarily with complete thyroid removal and lymph node dissection. Because it can be hereditary, all patients require RET genetic testing. Advanced cases are treated with targeted RET inhibitors and monitored using calcitonin blood tests.

Medullary Thyroid Carcinoma (MTC) is a unique and rare form of thyroid cancer. Unlike most other thyroid cancers that come from iodine-using follicular cells, MTC arises from C-cells (parafollicular cells) [1]. Because C-cells do not use iodine, radioactive iodine (RAI) therapy is not effective for MTC [2][3].

The Two Faces of MTC: Sporadic vs. Hereditary

MTC appears in two distinct ways, and knowing which one you have is the first step in management:

  • Sporadic MTC (75% of cases): This occurs by chance and is not passed down to children. It usually affects adults in their 40s or 50s [4].
  • Hereditary MTC (25% of cases): This is caused by an inherited genetic mutation in the RET gene, often as part of a syndrome called Multiple Endocrine Neoplasia type 2 (MEN2) [4][5].

Because hereditary MTC can be “silent” until it is advanced, germline RET genetic testing is mandatory for every person diagnosed with MTC, regardless of their age or family history [6][7]. If a mutation is found, your relatives may need testing to identify if they are at risk [8][9].

The Primary Treatment: Surgery

The standard of care for MTC is a total thyroidectomy (complete removal of the thyroid gland) [10]. Because MTC frequently spreads to nearby lymph nodes, surgeons almost always perform a central neck dissection (removing lymph nodes near the thyroid) [3][11].

If cancer is found in the lymph nodes on the side of the neck during imaging or physical exams, a lateral neck dissection may also be performed [12]. Surgery is most successful when performed by a high-volume surgeon who specializes in endocrine oncology [13].

Monitoring: The Power of “Doubling Time”

After surgery, doctors use blood tests for Calcitonin and CEA to monitor for any remaining or recurring cancer [14][15]. While the specific numbers are important, the most critical factor is the doubling time—how long it takes for these levels to double [16].

  • Slow Doubling Time: If it takes more than 2 years for levels to double, the cancer is likely growing very slowly and may not need immediate treatment [17].
  • Fast Doubling Time: If levels double in less than 6 months, it indicates a more aggressive disease that requires closer imaging (like CT or PET scans) and possibly systemic therapy [16][18].

Precision Medicine: RET Inhibitors

If MTC spreads (metastasizes) or cannot be fully removed with surgery, doctors use targeted drugs called Tyrosine Kinase Inhibitors (TKIs) [19].

The most modern and effective treatments are selective RET inhibitors, such as selpercatinib and pralsetinib [20][21]. These drugs specifically target the RET mutation that drives most MTC cases. Compared to older, multi-kinase inhibitors (like cabozantinib or vandetanib), selective RET inhibitors often have better tumor-shrinking results [20][22].

Important Note on Side Effects: While these therapies are highly effective, they are not without risk. TKIs are serious systemic therapies with significant side effects (such as high blood pressure, severe fatigue, diarrhea, and liver toxicity) [20][21]. They require close monitoring and management by an experienced medical oncologist, and are typically only started when there is clear evidence that the cancer is growing or causing symptoms [19][23].

Common questions in this guide

Why is radioactive iodine not used to treat Medullary Thyroid Carcinoma?
MTC develops in the C-cells of the thyroid gland, which do not absorb iodine. Because of this, radioactive iodine therapy, a common and effective treatment for other types of thyroid cancers, does not work for MTC.
Do I need genetic testing if I am diagnosed with MTC?
Yes, all patients diagnosed with MTC should undergo germline RET genetic testing regardless of age or family history. Up to 25% of cases are inherited, so finding a mutation helps guide your treatment and alerts family members who may also be at risk.
What is the main surgical treatment for MTC?
The standard surgical treatment is a total thyroidectomy to completely remove the thyroid gland. Surgeons also typically perform a central neck dissection to remove nearby lymph nodes, as MTC frequently spreads to these nodes early on.
What does calcitonin doubling time mean for my MTC prognosis?
Calcitonin doubling time measures how long it takes for your calcitonin blood levels to double after surgery. A slow doubling time (over two years) suggests slow-growing disease, while a fast doubling time (under six months) indicates aggressive cancer needing closer monitoring.
What treatments are available if Medullary Thyroid Carcinoma spreads?
If MTC spreads or cannot be removed with surgery, doctors use targeted drugs called Tyrosine Kinase Inhibitors (TKIs). The newest and most effective options are selective RET inhibitors, like selpercatinib and pralsetinib, which specifically target the mutation driving the cancer.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Has my blood been tested for a 'germline' RET mutation, and should my family members be tested as well?
  2. 2.Given that MTC doesn't respond to radioactive iodine, what is our plan for monitoring for recurrence?
  3. 3.Are my Calcitonin and CEA doubling times being calculated, and what do they tell us about my disease progression?
  4. 4.If I need systemic therapy, am I a candidate for a selective RET inhibitor like selpercatinib or pralsetinib?
  5. 5.What was the extent of my neck dissection, and were any 'occult' (hidden) cancer cells found in my lymph nodes?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    SEAP-GETNE consensus on prognostic and predictive molecular biomarkers in thyroid cancer.

    Ruz-Caracuel I, Alonso-Gordoa T, Hernández S, et al.

    Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia 2026; (59(2)):100859 doi:10.1016/j.patol.2026.100859.

    PMID: 41747300
  2. 2

    Updates on the Management of Thyroid Cancer.

    Araque KA, Gubbi S, Klubo-Gwiezdzinska J

    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2020; (52(8)):562-577 doi:10.1055/a-1089-7870.

    PMID: 32040962
  3. 3

    Risk Factors for Lateral Lymph Node Metastases in Patients With Sporadic Medullary Thyroid Carcinoma.

    Wu X, Li B, Zheng C, et al.

    Technology in cancer research & treatment 2020; (19()):1533033820962089 doi:10.1177/1533033820962089.

    PMID: 32964812
  4. 4

    RET Gene Alterations in Clinical Practice: A Comprehensive Review and Database Update.

    Ricciardi Tenore C, Tulli E, Perrucci A, et al.

    Genes 2025; (16(12)) doi:10.3390/genes16121472.

    PMID: 41465145
  5. 5

    Current status of the prognostic molecular markers in medullary thyroid carcinoma.

    Oczko-Wojciechowska M, Czarniecka A, Gawlik T, et al.

    Endocrine connections 2020; (9(12)):R251-R263.

    PMID: 33112827
  6. 6

    Histopathology of C Cells and Medullary Thyroid Carcinoma.

    Cameselle-Teijeiro JM, Sobrinho-Simões M

    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 2025; (223()):9-50 doi:10.1007/978-3-031-80396-3_2.

    PMID: 40102253
  7. 7

    Prophylactic thyroidectomy in children with multiple endocrine neoplasia type 2.

    Prete FP, Abdel-Aziz T, Morkane C, et al.

    The British journal of surgery 2018; (105(10)):1319-1327 doi:10.1002/bjs.10856.

    PMID: 29663329
  8. 8

    [30 years of prophylactic thyroidectomy for hereditary medullary thyroid cancer : A milestone in translational medicine].

    Dralle H, Weber F, Lorenz K, Machens A

    Chirurgie (Heidelberg, Germany) 2024; (95(8)):638-650 doi:10.1007/s00104-024-02105-x.

    PMID: 38806713
  9. 9

    Results and Clinical Interpretation of Germline RET Analysis in a Series of Patients with Medullary Thyroid Carcinoma: The Challenge of the Variants of Uncertain Significance.

    Innella G, Rossi C, Romagnoli M, et al.

    Cancers 2020; (12(11)) doi:10.3390/cancers12113268.

    PMID: 33167350
  10. 10

    Approach to lymph node metastases in sporadic medullary thyroid carcinoma An istitutional experience.

    Polistena A, Monacelli M, Lucchini R, et al.

    Annali italiani di chirurgia 2015; (86()):390-5.

    PMID: 26567553
  11. 11

    Long-term outcome of prophylactic thyroidectomy in children carrying RET germline mutations.

    Machens A, Elwerr M, Lorenz K, et al.

    The British journal of surgery 2018; (105(2)):e150-e157 doi:10.1002/bjs.10746.

    PMID: 29341155
  12. 12

    Medullary thyroid cancer: What is the optimal management of the lateral neck in a node negative patient at index operation?

    Szabo Yamashita T, Rogers RT, Foster TR, et al.

    Surgery 2022; (171(1)):177-181 doi:10.1016/j.surg.2021.04.052.

    PMID: 34284893
  13. 13

    Timing and extension of lymphadenectomy in medullary thyroid carcinoma: A case series from a single institution.

    Polistena A, Sanguinetti A, Lucchini R, et al.

    International journal of surgery (London, England) 2017; (41 Suppl 1()):S70-S74 doi:10.1016/j.ijsu.2017.04.026.

    PMID: 28506418
  14. 14

    "Triple-negative" non-secretory medullary thyroid cancer: uncommon pathological findings in a rare disease.

    Martínez-Montoro JI, Gómez-Pérez AM, Gallego E, et al.

    Archives of medical science : AMS 2022; (18(3)):825-828 doi:10.5114/aoms/147431.

    PMID: 35591839
  15. 15

    Serum Biochemical Markers for Medullary Thyroid Carcinoma: An Update.

    Liu S, Zhao H, Li X

    Cancer management and research 2024; (16()):299-310 doi:10.2147/CMAR.S440477.

    PMID: 38617188
  16. 16

    Update on Management of Medullary Thyroid Carcinoma: Focus on Nuclear Medicine.

    Treglia G, Rufini V, Piccardo A, Imperiale A

    Seminars in nuclear medicine 2023; (53(4)):481-489 doi:10.1053/j.semnuclmed.2023.01.003.

    PMID: 36702731
  17. 17

    Spontaneous Deceleration and Acceleration of Growth Rate in Medullary Thyroid Carcinomas Suggested by Changes in Calcitonin Doubling Times Over Long-Term Surveillance.

    Miyauchi A, Kudo T, Kihara M, et al.

    World journal of surgery 2019; (43(2)):504-512 doi:10.1007/s00268-018-4789-1.

    PMID: 30229381
  18. 18

    Calcitonin doubling time in medullary thyroid carcinoma after the detection of distant metastases keenly predicts patients' carcinoma death.

    Ito Y, Miyauchi A, Kihara M, et al.

    Endocrine journal 2016; (63(7)):663-7 doi:10.1507/endocrj.EJ16-0140.

    PMID: 27097545
  19. 19

    Systemic therapies for medullary thyroid carcinoma: state of the art.

    Román-González A, Califano I, Concepción-Zavaleta M, et al.

    Therapeutic advances in endocrinology and metabolism 2025; (16()):20420188251336091 doi:10.1177/20420188251336091.

    PMID: 40356795
  20. 20

    Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.

    Hadoux J, Elisei R, Brose MS, et al.

    The New England journal of medicine 2023; (389(20)):1851-1861 doi:10.1056/NEJMoa2309719.

    PMID: 37870969
  21. 21

    Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.

    Wirth LJ, Sherman E, Robinson B, et al.

    The New England journal of medicine 2020; (383(9)):825-835 doi:10.1056/NEJMoa2005651.

    PMID: 32846061
  22. 22

    State of the art and future directions in the systemic treatment of medullary thyroid cancer.

    Jager EC, Broekman KE, Kruijff S, Links TP

    Current opinion in oncology 2022; (34(1)):1-8 doi:10.1097/CCO.0000000000000798.

    PMID: 34669647
  23. 23

    Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer.

    Hadoux J, Schlumberger M

    Best practice & research. Clinical endocrinology & metabolism 2017; (31(3)):335-347 doi:10.1016/j.beem.2017.04.009.

    PMID: 28911729

This page provides educational information about Medullary Thyroid Carcinoma (MTC) management. Always consult your endocrinologist or oncologist to determine the best testing and treatment plan for your specific diagnosis.

Get notified when new evidence is published on Rare thyroid carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.